Understand the source comparison
Best Weight Loss & Metabolic Peptides 2026: Efficacy Comparison
The table below compares the leading peptides in metabolic and weight loss research based on Phase II and III trial data published through 2026. The 'Professional Assessment' column reflects mechanisms, side effect profiles, and research applicability. Retatru
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares the leading peptides in metabolic and weight loss research based on Phase II and III trial data published through 2026. The 'Professional Assessment' column reflects mechanisms, side effect profiles, and research applicability.
- Retatrutide
- GLP-1 / GIP / Glucagon triple agonist
- 24.2% (48 weeks, 12mg)
- Highest weight reduction; significant visceral fat and liver fat reduction
- Moderate (30-40% nausea during titration)
- Strongest efficacy data; glucagon component increases energy expenditure—ideal for MASLD research
- Tirzepatide
- GLP-1 / GIP dual agonist
- 20.9% (72 weeks, 15mg)
- Enhanced insulin sensitivity; adipose tissue inflammation reduction
- Moderate (30-45% nausea during titration)
- Well-tolerated dual agonist; proven long-term data; best balance of efficacy and safety profile
- Semaglutide
- GLP-1 receptor agonist
- 14.9% (68 weeks, 2.4mg)
- Cardiometabolic improvements; HbA1c reduction 1.5-2.0%
- Moderate (25-35% nausea during titration)
- Most extensively studied GLP-1 monotherapy; reliable efficacy; 7-day half-life allows weekly dosing
- Survodutide
- GLP-1 / Glucagon dual agonist
- 15.7% (46 weeks)
- 42% liver fat reduction; strong MASLD endpoint data
- Moderate to high (40-50% GI events)
- Glucagon pathway enhances hepatic fat oxidation; particularly relevant for liver fat research
- Mazdutide
- 15-18% (estimated, Phase II)
- HbA1c and fasting insulin improvements
- Moderate (35-45% nausea)
- Similar mechanism to survodutide; additional glucose homeostasis benefits
- 5-Amino-1MQ
- NNMT inhibitor / AMPK activator
- 30% visceral fat reduction (preclinical, 10 weeks)
- Shifts metabolism toward fat oxidation without appetite suppression
- Minimal to none
- No GI side effects; mechanistically distinct from incretin agonists; human trial data limited
- AOD9604
- hGH fragment / beta-3 adrenergic agonist
- 2-3 kg (12 weeks)
- Preferential abdominal fat reduction; no insulin resistance
- Modest efficacy; no appetite suppression; useful for targeted fat research without metabolic interference
- Tesofensine
- Triple monoamine reuptake inhibitor
- 9.2-12.8% (24 weeks, 0.5-1.0mg)
- Increased thermogenesis and energy expenditure
- Low GI; elevated heart rate/BP in some subjects
- Strong efficacy; cardiovascular monitoring required; remains investigational